Videoclip: Molecular Biology of GBM
Watch this brief video of a radiation oncologist, neurosurgeon, and neuro-oncologist, discussing tre
MORE  |
|
Evaluating New Brain Masses
Patients who present with newly diagnosed brain masses usually have some symptomatic combination of
MORE |
|
Treating the Elderly with Malignant Glioma
Is 70 the "New 60”?
When considering how aggressively to treat an elderly patient with
MORE |
|
Recurrent GBM
Unfortunately, almost all glioblastomas (GBMs) recur despite aggressive treatment with surgery, radi
MORE |
|
MGMT and Its Role in GBM
Combining temozolomide (TMZ), an oral cytotoxic agent with concomitant radiation therapy (XRT) has b
MORE |
|
Treating Newly Diagnosed GBM
Glioblastoma multiforme (GBM) is a primary brain tumor classified by the World Health Organization a
MORE |
|
Future Hope for Long-Term GBM Survival?
The conversation around prognosis for a patient with newly diagnosed glioblastoma is becoming increa
MORE |
|
Polymer-Based Local Therapy
High-grade gliomas are aggressive tumors that usually recur locally despite aggressive multimodality
MORE |
|
Newly Diagnosed Oligos
Treatment for newly diagnosed anaplastic oligodendrogliomas is controversial. Oligodendrogliomas ar
MORE |
|
Imaging Alternatives
Conventional computed tomography (CT) and magnetic resonance imaging (MRI) scans provide structural
MORE |
|
The PK of TMZ
Temozolomide (TMZ), an oral alkylating agent, is rapidly absorbed and spontaneously converts to the
MORE |
|
The Role of MGMT
Cytotoxic stress by chemotherapy or radiation induces upregulation of methyl-guanine methyl transfer
MORE |
|
New Standard of Care for GBM
Phase II data initially suggested that temozolomide (TMZ) may be efficacious for malignant gliomas w
MORE |
|
Molecular Markers
There’s a lot of excitement about molecular markers such as methyl-guanine methyltransferase (MGMT),
MORE |
|
